IGFBP-3-dependent breast cancer cell chemoresistance, while contrary to studies in some other cancers showing IGFBP-3-dependent chemosensitivity, might in part explain the association between high IGFBP-3 (and EGFR) expression and poor patient outcomes in women with ER-negative breast cancer. This evidence concerns the gene IGFBP3 and breast carcinoma.